Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: init...
Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
About this item
Full title
Author / Creator
Publisher
Germany
Journal title
Language
English
Formats
Publication information
Publisher
Germany
Subjects
More information
Scope and Contents
Contents
Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbe...
Alternative Titles
Full title
Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_30506283
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_30506283
Other Identifiers
E-ISSN
1619-7089
DOI
10.1007/s00259-018-4209-7
